Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET2 | Q6N021 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TET3 | O43151 | 1/20 | 0.33 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL637535 | 0.94 | TBXAS1 (0.35) | TET2MEN1KMT2ATET3TET1 | |
| SCHEMBL3284744 | 0.92 | TBXAS1 (0.37) | TET2MEN1KMT2ATET3TET1 | |
| SCHEMBL636321 | 0.88 | MEN1 (0.36) | TET2MEN1KMT2ATET3TET1 | |
| SCHEMBL4417775 | 0.86 | TET2 (0.36) | TET2TET3TET1TBXAS1GRIK1 | |
| SCHEMBL11573126 | 0.83 | TET2 (0.31) | TET2TET3TET1TBXAS1 | |
| SCHEMBL6681392 | 0.82 | TET2 (0.32) | TET2TET3TET1TBXAS1GRIK1 | |
| SCHEMBL5515961 | 0.81 | TET2 (0.35) | TET2TET3TET1TBXAS1GRIK1 | |
| SCHEMBL8743488 | 0.80 | KDM4A (0.33) | TET2TET3TET1 | |
| SCHEMBL20366389 | 0.79 | MEN1 (0.36) | MEN1KMT2A | |
| SCHEMBL4928619 | 0.79 | LMNA (0.46) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4455168-B1 | VISIBLE LIGHT CURABLE COMPOSITION AND VISIBLE LIGHT CURABLE COMPOSITION POLYMERIZATION METHOD | CHT TURKEY KIMYA SANAYI VE TICARET A S (TR) | 2025-12-24 | — | — | EP | claimed |
| EP-3872573-B1 | TONER ADDITIVE FORMULATION WITH CROSS-LINKED ORGANIC POLYMERIC ADDITIVE | XEROX CORP (US) | 2025-04-09 | — | — | EP | claimed |
| EP-3395876-B1 | NOVEL NANOPARTICLES | COVESTRO NETHERLANDS BV (NL) | 2024-07-31 | — | — | EP | claimed |
| EP-3368593-B1 | IMPROVED BINDER COMPOSITIONS AND USES THEREOF | KNAUF INSULATION SPRL (BE) | 2023-12-06 | — | — | EP | claimed |
| EP-3870236-B1 | NANOPARTICLE ENCAPSULATION TO TARGET G PROTEIN-COUPLED RECEPTORS IN ENDOSOMES | TAKEDA PHARMACEUTICALS CO (JP) | 2023-08-09 | — | — | EP | claimed |
| EP-3571293-B1 | A THERMORESPONSIVE MICROCARRIER SYSTEM AND USES THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2023-04-12 | — | — | EP | claimed |
| EP-3720890-B1 | USE OF ANTIMICROBIAL ETHYLENE COPOLYMERS FOR PACKAGING APPLICATIONS | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2022-12-28 | — | — | EP | claimed |
| EP-3368207-B1 | ENCAPSULATION | ENCAPSYS LLC (US) | 2021-12-01 | — | — | EP | claimed |
| US-20190117799-A1 | STIMULI-RESPONSIVE NANOPARTICLES FOR BIOMEDICAL APPLICATIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-04-25 | — | — | US | claimed |
| EP-2951216-B1 | ANTI-MICROBIAL POLYMER | FACHHOCHSCHULE MUENSTER (DE) | 2018-07-18 | — | — | EP | claimed |
| WO-2010072834-A1 | NUCLEIC ACID PURIFICATION METHOD | QIAGEN GMBH (DE) | 2010-07-01 | — | — | WO | claimed |
| EP-1842601-B1 | Method for forming functional layers | CIBA HOLDING INC (CH) | 2009-07-22 | — | — | EP | claimed |
| US-20090103045-A1 | SILICONE HYDROGELS WITH AMINO SURFACE GROUPS | SALIX PHARMACEUTICALS, INC. | 2009-04-23 | — | — | US | claimed |
| US-20070244248-A1 | Copolymers useful as demulsifiers and clarifiers | BAKER HUGHES INCORPORATED (US) | 2007-10-18 | — | — | US | claimed |
| EP-1842601-A1 | Method for forming functional layers | Ciba Specialty Chemicals Holding Inc. (CH) | 2007-10-10 | — | — | EP | claimed |
| US-20070113353-A1 | Polymeric Surface Treatment Compositions | THE CLOROX COMPANY | 2007-05-24 | — | — | US | claimed |
| JP-2006511344-A | — | — | 2006-04-06 | — | — | JP | claimed |
| EP-1572379-A2 | METHOD FOR FORMING FUNCTIONAL LAYERS | Ciba SC Holding AG (CH) | 2005-09-14 | — | — | EP | claimed |
| WO-2004056496-A2 | METHOD FOR FORMING FUNCTIONAL LAYERS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2004-07-08 | — | — | WO | claimed |
| EP-0420687-B1 | Discoloration-resistant spandex | DU PONT (US) | 1996-06-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117799-A1 | STIMULI-RESPONSIVE NANOPARTICLES FOR BIOMEDICAL APPLICATIONS | HSPA9, LRBA, AHSA1 | TET2 4836/4885MEN1 1698/4885KMT2A 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.